Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease

Brain

Volumn 131, Issue 1, 2008, Pages 120-131

  Kish, Stephen J ^a   Tong, Junchao ^a   Hornykiewicz, Oleh ^b   Rajput, Ali ^c   Chang, Li Jan ^a   Guttman, Mark ^a,d   Furukawa, Yoshiaki ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Medical University of Vienna   (Austria)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d Centre for Movement Disorders   (Canada)

Author keywords

Caudate; Dyskinesia; Parkinson's disease; Putamen; Serotonin transporter

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DOPAMINE; LEVODOPA; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

ADULT; AGED; ARTICLE; AUTOPSY; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DYSKINESIA; ENZYME BLOOD LEVEL; FEMALE; FUNCTIONAL DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NERVE CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAPHE NUCLEUS; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE CELL; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CAUDATE NUCLEUS; DOPAMINE; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; LEVODOPA; MALE; PARKINSON DISEASE; PUTAMEN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTOPHAN HYDROXYLASE;

EID: 37549029102     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm239     Document Type: Article

References (56)

1. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-81.
2. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 1994; 667: 295-9.
3. Arai R, Karasawa N, Geffard M, Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995; 195: 195-8.
4. Berger B, Glowinski J. Dopamine uptake in serotoninergic terminals in vitro: a valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures. Brain Res 1978; 147: 29-45.
5. Bernheimer H, Birkmayer W, Hornykiewicz O. Verteilung des 5-hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patientin mit Parkinson-Syndrom. Klin Wochenschr 1961; 39: 1056-9.
6. Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, et al. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 1984; 231: 343-54.
7. Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 2003; 18: 241-53.
8. Carkaci-Salli N, Flanagan JM, Martz MK, Salli U, Walther DJ, Bader M, et al. Functional domains of human tryptophan hydroxylase 2 (hTPH2). J Biol Chem 2006; 281: 28105-12.
9. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130: 1819-33.
10. Carter CJ, Pycock CJ. The effects of 5,7-dihydroxytryptamine lesions of extrapyramidal and mesolimbic sites on spontaneous motor behaviour, and amphetamine-induced stereotypy. Naunyn Schmiedebergs Arch Pharmacol 1979; 308: 51-4.
11. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 1993; 54: 691-9.
12. D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987; 22: 229-36.
13. de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127: 2747-54.
14. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des menches und ihr Verhalten bei Erkrankungen des extrapyramiden Systems. Klin Wochenschr 1960; 38: 1236-9.
15. Erinoff L, Snodgrass SR. Effects of adult or neonatal treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine on locomotor activity, monoamine levels, and response to caffeine. Pharmacol Biochem Behav 1986; 24: 1039-45.
16. Gaspar P, Febvret A, Colombo J. Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 1993; 96: 100-6.
17. Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007; 14: 523-8.
18. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990; 510: 104-7.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
20. Iravani MM, Jackson MJ, Kuoppamäki M, Smith LA, Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J Neurosci 2003; 23: 9107-15.
21. Iwamoto ET, Loh HH, Way EL. Circling behavior in rats with 6-hydroxydopamine or electrolytic nigral lesions. Eur J Pharmacol 1976; 37: 339-56.
22. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1986; 45: 1-18.
23. Karstaedt PJ, Kerasidis H, Pincus JH, Meloni R, Graham J, Gale K. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp Neurol 1994; 126: 25-30.
24. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003; 60: 1223-9.
25. Kish SJ. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol 2003; 91: 39-49.
26. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876-80.
27. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 2005; 32: 123-8.
28. Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, et al. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 2003; 343: 17-20.
29. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 2005; 1046: 230-3.
30. Mann DM, Yates PO. Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol 1983; 9: 3-19.
31. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001; 158: 1843-9.
32. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004; 61: 1271-9.
33. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86-102.
34. Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of cerebral monoamines. Science 1970; 170: 76-7.
35. Ng KY, Colburn RW, Kopin IJ. Effects of L-dopa on efflux of cerebral monoamines from synaptosomes. Nature 1971; 230: 331-2.
36. Parent A, Mackey A, De Bellefeuille L. The subcortical afferents to caudate nucleus and putamen in primate: a fluorescence retrograde double labeling study. Neuroscience 1983; 10: 1137-50.
37. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50: 743-55.
38. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67: 1612-7.
39. Qian Y, Melikian HE, Rye DB, Levey AI, Blakely RD. Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J Neurosci 1995; 15: 1261-74.
40. Raisman R, Cash R, Agid Y. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 1986; 36: 556-60.
41. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 1998; 245: 151-4.
42. Sakowski SA, Geddes TJ, Thomas DM, Levi E, Hatfield JS, Kuhn DM. Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res 2006; 1085: 11-8.
43. Sawada M, Nagatsu T, Nagatsu I, Ito K, Iizuka R, Kondo T, et al. Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients. J Neural Transm 1985; 62: 107-15.
44. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983; 275: 321-8.
45. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-12.
46. Schwarting R, Carey RJ. Deficits in inhibitory avoidance after neurotoxic lesions of the ventral striatum are neurochemically and behaviorally selective. Behav Brain Res 1985; 18: 279-83.
47. Snyder AM, Zigmond MJ, Lund RD. Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J Comp Neurol 1986; 245: 274-81.
48. Stachowiak MK, Bruno JP, Snyder AM, Stricker EM, Zigmond MJ. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res 1984; 291: 164-7.
49. Takeuchi Y, Sawada T, Blunt S, Jenner P, Marsden CD. Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res 1991; 562: 301-5.
50. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 10: 631-4.
51. Tong J, Hornykiewicz O, Furukawa Y, Kish SJ. Marked dissociation between high noradrenaline vs. low noradrenaline transporter levels in human nucleus accumbens. J Neurochem 2007; 102: 1691-702.
52. Wilson JM, Nobrega JN, Carroll ME, Niznik HB, Shannak K, Lac ST, et al. Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J Neurosci 1994; 14: 2966-79.
53. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996; 47: 718-26.
54. Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, et al. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 2006; 31: 2639-51.
55. Zhou FC, Bledsoe S, Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 1991; 556: 108-16.
56. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989; 26: 41-6.